ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Sandip Patel discusses the impact of adding chemotherapy in patients progressing on 1L osimertinib. (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Sandip Patel discusses the impact of adding chemotherapy in patients progressing on 1L osimertinib. (Video 1/3)

    Published Aug 12, 2026

    S

    Sandip Patel, MD

    Medical Professional

    OsiContinuation COMPEL

    More in this series: OsiContinuation_2026
    Dr. Sandip Patel reviews the benefit of adding local consolidative treatment to 1L osimertinib in EGFRm mNSCLC. (Video 2/3)

    Dr. Sandip Patel reviews the benefit of adding local consolidative treatment to 1L osimertinib in EGFRm mNSCLC. (Video 2/3)

    OsiContinuation NORTHSTAR

    Sandip Patel, MD
    Lung Cancer
    Dr. Sandip Patel describes re-challenging with chemotherapy in patients who received 1L osimertinib + chemotherapy. (Video 3/3)

    Dr. Sandip Patel describes re-challenging with chemotherapy in patients who received 1L osimertinib + chemotherapy. (Video 3/3)

    OsiContinuation Rechallenge

    Sandip Patel, MD
    Lung Cancer
    Related Videos
    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)

    Eytan Stein, MD
    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Dr. Wade Iams reviews the efficacy of dose interruption/reduction strategies for patients with EGFRm mNSCLC on 1L amivantamab + lazertinib (Video 2/3)

    Wade Iams, MD
    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    What sets iberdomide apart from established IMiDs? Dr. Rahul Banerjee explains. (Video 1/3)

    Rahul Banerjee, MD
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD